Statement of Changes in Beneficial Ownership (4)

FORM 4 [X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* COLA MICHAEL F	2. Issuer Name and Ticker or Trading Symbol Aevi Genomic Medicine, Inc. [ GNMX ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) President and CEO
(Last) (First) (Middle) C/O AEVI GENOMIC MEDICINE, INC., 435 DEVON PARK DRIVE, SUITE 715	3. Date of Earliest Transaction (MM/DD/YYYY) 2/3/2020
(Street) WAYNE, PA 19087 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	2/3/2020		D		2267859	D	⁽¹⁾	0	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Purchase)	$6.45	2/3/2020		D			17327	⁽²⁾	4/16/2024	Common Stock	17327	$0	0	D
Stock Option (Right to Purchase)	$7.01	2/3/2020		D			292087	⁽³⁾	2/18/2025	Common Stock	292087	$0	0	D
Stock Option (Right to Purchase)	$4.83	2/3/2020		D			250000	⁽⁴⁾	4/15/2026	Common Stock	250000	$0	0	D
Stock Option (Right to Purchase)	$4.91	2/3/2020		D			250000	⁽⁵⁾	2/17/2027	Common Stock	250000	$0	0	D
Stock Option (Right to Purchase)	$1.51	2/3/2020		D			450000	⁽⁶⁾	5/14/2028	Common Stock	450000	$0	0	D
Stock Option (Right to Purchase)	$1.55	2/3/2020		D			661000	⁽⁷⁾	4/17/2028	Common Stock	661000	$0	0	D
Stock Option (Right to Purchase)	$1.32	2/3/2020		D			50000	⁽⁸⁾	8/11/2027	Common Stock	50000	$0	0	D
Stock Option (Right to Purchase)	$4.22	2/3/2020		D			1500000	⁽⁹⁾	9/13/2023	Common Stock	1500000	$0	0	D
Warrant (Right to Buy)	$2.84	2/3/2020		D			21181	⁽¹⁰⁾	10/17/2022	Common Stock	21181	$0	0	D

Explanation of Responses:
(1)	Disposed of as a result of the merger pursuant to the previously announced Agreement and Plan of Merger and Reorganization by and among Cerecor Inc. ("Cerecor"), Genie Merger Sub, Inc., Second Genie Merger Sub, LLC and issuer (the "Merger"). At the effective time of the Merger, holders of issuer common stock received (A) the fraction of a share of Cerecor common stock equal to the exchange ratio of 0.0334 (B) one contingent value right, which represents the right to receive contingent payments upon the achievement of certain milestones and (C) cash in lieu of any fractional shares of Cerecor common stock.
(2)	This option, which became exercisable on April 16, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
(3)	This option, which became exercisable on February 18, 2015, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger
(4)	This option, which became exercisable on April 15, 2017, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger
(5)	This option, which became exercisable on February 17, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger
(6)	This option, which became exercisable on May 14, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger
(7)	This option, which became exercisable on April 17, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
(8)	This option, which became exercisable on August 11, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
(9)	This option which became exercisable on September 13, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
(10)	This warrant, which was issued pursuant to a Securities Purchase Agreement dated August 9, 2017, was subsequently amended by the Amendment Agreement of Warrants to Purchase Common Stock dated December 5, 2019, whereby immediately prior to the Merger the warrants were automatically exercised in a cashless exercise. Given the exercise price of the outstanding warrants, the cashless exercise resulted in no shares of common stock being issued and the warrant was rendered null and void.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
COLA MICHAEL F C/O AEVI GENOMIC MEDICINE, INC. 435 DEVON PARK DRIVE, SUITE 715 WAYNE, PA 19087	X		President and CEO